Literature DB >> 2139669

Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist.

W P Arend1, H G Welgus, R C Thompson, S P Eisenberg.   

Abstract

Human monocytes cultured on adherent IgG produce a specific IL-1 inhibitor that functions as a receptor antagonist (IL-1ra). This molecular has been purified, sequenced, cloned as a cDNA, and expressed in Escherichia coli. Recombinant IL-1ra has 17,000 mol wt and binds to IL-1 receptors on T lymphocytes, synovial cells, and chondrocytes with an affinity nearly equal to that of IL-1. These studies have examined some biological properties of purified recombinant human IL-1ra. This protein exhibits a dose-responsive inhibition of Il-1 alpha and Il-1 beta augmentation of PHA-induced murine thymocyte proliferation. The recombinant IL-1ra also blocks IL-1 alpha and IL-1 beta stimulation of PGE2 production in human synovial cells and rabbit articular chondrocytes, and of collagenase production by the synovial cells. A 50% inhibition of these IL-1-induced biological responses requires amounts of IL-1ra up to 100-fold in excess of the amounts of IL-1 alpha or IL-1 beta present. IL-1ra may play an important role in normal physiology or in pathophysiological states by functioning as a natural IL-1 receptor antagonist in the cell microenvironment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139669      PMCID: PMC296623          DOI: 10.1172/JCI114622

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

Review 1.  Native interleukin 1 inhibitors.

Authors:  J W Larrick
Journal:  Immunol Today       Date:  1989-02

2.  Two high-affinity interleukin 1 receptors represent separate gene products.

Authors:  R Chizzonite; T Truitt; P L Kilian; A S Stern; P Nunes; K P Parker; K L Kaffka; A O Chua; D K Lugg; U Gubler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-10       Impact factor: 11.205

Review 3.  Interleukin-1 and its biologically related cytokines.

Authors:  C A Dinarello
Journal:  Adv Immunol       Date:  1989       Impact factor: 3.543

4.  Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans.

Authors:  K Bendtzen; T Mandrup-Poulsen; J Nerup; J H Nielsen; C A Dinarello; M Svenson
Journal:  Science       Date:  1986-06-20       Impact factor: 47.728

5.  A urine inhibitor of interleukin 1 activity affects both interleukin 1 alpha and 1 beta but not tumor necrosis factor alpha.

Authors:  P Seckinger; K Williamson; J F Balavoine; B Mach; G Mazzei; A Shaw; J M Dayer
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

6.  Analysis of 6-keto PGF1 alpha, 5-HETE, and LTC4 in rat lung: comparison of GM/MS, RIA, and EIA.

Authors:  J Y Westcott; S Chang; M Balazy; D O Stene; P Pradelles; J Maclouf; N F Voelkel; R C Murphy
Journal:  Prostaglandins       Date:  1986-12

7.  Uromodulin. An immunosuppressive 85-kilodalton glycoprotein isolated from human pregnancy urine is a high affinity ligand for recombinant interleukin 1 alpha.

Authors:  A V Muchmore; J M Decker
Journal:  J Biol Chem       Date:  1986-10-15       Impact factor: 5.157

8.  A urine inhibitor of interleukin 1 activity that blocks ligand binding.

Authors:  P Seckinger; J W Lowenthal; K Williamson; J M Dayer; H R MacDonald
Journal:  J Immunol       Date:  1987-09-01       Impact factor: 5.422

9.  An IL-1 inhibitor from human monocytes. Production and characterization of biologic properties.

Authors:  W P Arend; F G Joslin; R C Thompson; C H Hannum
Journal:  J Immunol       Date:  1989-09-15       Impact factor: 5.422

10.  A human urine-derived interleukin 1 inhibitor. Homology with deoxyribonuclease I.

Authors:  D L Rosenstreich; J H Tu; P R Kinkade; I Maurer-Fogy; J Kahn; R W Barton; P R Farina
Journal:  J Exp Med       Date:  1988-11-01       Impact factor: 14.307

View more
  125 in total

Review 1.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

Review 2.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

3.  IL-1 receptor accessory protein-Ig/IL-1 receptor type II-Ig heterodimer inhibits IL-1 response more strongly than other IL-1 blocking biopharmaceutical agents.

Authors:  Haruo Hanawa; Yoshimi Ota; Limin Ding; He Chang; Kaori Yoshida; Keita Otaki; Kazuhisa Hao; Sou Kasahara; Makoto Kodama; Mikio Nakazawa; Yoshifusa Aizawa
Journal:  J Clin Immunol       Date:  2010-12-22       Impact factor: 8.317

4.  Is there a causal role for IL-1 in postmenopausal bone loss?

Authors:  R Pacifici
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

5.  Selective and early increase of IL-1 inhibitors, IL-6 and cortisol after elective surgery.

Authors:  F Di Padova; C Pozzi; M J Tondre; R Tritapepe
Journal:  Clin Exp Immunol       Date:  1991-07       Impact factor: 4.330

6.  Anti-human immunodeficiency virus type 1 microbicide cellulose acetate 1,2-benzenedicarboxylate in a human in vitro model of vaginal inflammation.

Authors:  R N Fichorova; F Zhou; V Ratnam; V Atanassova; S Jiang; N Strick; A R Neurath
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 7.  Efficacy, tolerability and cost effectiveness of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis.

Authors:  Michael T Nurmohamed; Ben A C Dijkmans
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 8.  Effective Strategies for the Management of Pyoderma Gangrenosum.

Authors:  Heidi Goodarzi; Raja K Sivamani; Miki Shirakawa Garcia; Lisa N Wehrli; Hilary Craven; Yoko Ono; Emanual Maverakis
Journal:  Adv Wound Care (New Rochelle)       Date:  2012-10       Impact factor: 4.730

9.  Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats.

Authors:  R B Kimble; J L Vannice; D C Bloedow; R C Thompson; W Hopfer; V T Kung; C Brownfield; R Pacifici
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

10.  Interleukin-1 is involved in mouse resistance to Mycobacterium avium.

Authors:  M Denis; E Ghadirian
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.